MW Ozempic maker's stock surges. A trial of a new Novo Nordisk drug shows promise.
By Steve Goldstein
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.
Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram once-per-week dose taken for 36 weeks.
This trial was done by injecting patients - which is how popular drugs Ozempic and Wegovy are administered - but it's also being developed for oral administration.
It said most of the side effects were gastrointestinal and mild to moderate in severity.
Novo Nordisk said it is now planning further clinical development of amycretin in adults with overweight or obesity.
Novo Nordisk stock (DK:NOVO.B) $(NVO)$ rallied 12% in Copenhagen trade, though it's still down about 13% from where it was after a disappointing trial of CagriSema.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
January 24, 2025 08:47 ET (13:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。